Skip to main content
Premium Trial:

Request an Annual Quote

... As Firm Secures Rights to RNAture s Nucleic Acid Purification Products from Hitachi

NEW YORK, May 3 (GenomeWeb News) - Qiagen said today that it has acquired the worldwide exclusive rights and licenses to manufacture and market all of RNAture's nucleic acid isolation products from its parent company, HitachiChemicalResearchCenter.

 

Pursuant to the companies' agreement, Hitachi Chemical Research will transfer all current commercial operations to Qiagen. Additional terms were not disclosed. Qiagen said it does not expect the transaction to have a material impact on its financial outlook for 2005.

 

According to Qiagen, RNAture's product portfolio focuses on mRNA isolation products and comprises solutions for the capture of cellular poly(A)+ RNA in the wells of specially treated microplates, and includes products marketed under the GenePlate name.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.